Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
NCT02063997Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of arhalofenate in gout, sponsored by Gilead Sciences. Started Mar 2014; status: completed.
02
Drugs
arhalofenate
03
Conditions
gout
Beyond the preview
Go deeper on NCT02063997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063997.